Back to top
more

CytoDyn (CYDY)

(Delayed Data from OTC)

$0.15 USD

0.15
758,483

+0.01 (4.61%)

Updated May 8, 2024 03:57 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (97 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CYDY

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

CytoDyn Inc. [CYDY]

Reports for Purchase

Showing records 21 - 40 ( 82 total )

Company: CytoDyn Inc.

Industry: Medical - Drugs

Record: 21

03/30/2020

Company Report

Pages: 5

Promising Preliminary Results in COVID-19 Patients; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 10.00

Research Provided by a Third Party

Company: CytoDyn Inc.

Industry: Medical - Drugs

Record: 22

03/20/2020

Company Report

Pages: 6

Leronlimab Administered to COVID-19 Patients; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: CytoDyn Inc.

Industry: Medical - Drugs

Record: 23

03/09/2020

Company Report

Pages: 5

Leronlimab COVID-19 Trial Application Submitted; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 10.00

Research Provided by a Third Party

Company: CytoDyn Inc.

Industry: Medical - Drugs

Record: 24

03/06/2020

Company Report

Pages: 6

Leronlimab Filing Completion Imminent; Coronavirus Phase 2 Trial Application; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: CytoDyn Inc.

Industry: Medical - Drugs

Record: 25

02/10/2020

Industry Report

Pages: 14

Tracking the Course of the Coronavirus Epidemic: KOL Conference Call Recap

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 50.00

Research Provided by a Third Party

Company: CytoDyn Inc.

Industry: Medical - Drugs

Record: 26

02/07/2020

Company Report

Pages: 6

Regulatory Filing Completion Imminent; Phase 2 Cancer Basket Trial Filed; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: CytoDyn Inc.

Industry: Medical - Drugs

Record: 27

01/23/2020

Company Report

Pages: 6

Updated Breast Cancer Data Support Application for Breakthrough Therapy Designation; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: CytoDyn Inc.

Industry: Medical - Drugs

Record: 28

12/24/2019

Company Report

Pages: 6

Leronlimab Positive Breast Cancer Clinical Update; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: CytoDyn Inc.

Industry: Medical - Drugs

Record: 29

12/19/2019

Company Report

Pages: 7

U.S. Commercialization Agreement Inked; Regulatory Filing Completion Imminent; Reiterate Buy; Raising PT to $1.50

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: CytoDyn Inc.

Industry: Medical - Drugs

Record: 30

10/01/2019

Company Report

Pages: 6

Regulatory Filing for HIV on Track; First Breast Cancer Patient Dosed; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: CytoDyn Inc.

Industry: Medical - Drugs

Record: 31

09/16/2019

Company Report

Pages: 6

Biologics License Application Filing Completion Expected in 4Q19; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: CytoDyn Inc.

Industry: Medical - Drugs

Record: 32

09/05/2019

Company Report

Pages: 6

Investigational New Drug Application and Phase 2 Protocol for NASH With Leronlimab Filed; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: CytoDyn Inc.

Industry: Medical - Drugs

Record: 33

08/15/2019

Company Report

Pages: 6

Leronlimab Monotherapy Data Updated; FY2019 Results Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: CytoDyn Inc.

Industry: Medical - Drugs

Record: 34

08/06/2019

Company Report

Pages: 6

BLA Filing for Leronlimab on Track; Application Fees Waived; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: CytoDyn Inc.

Industry: Medical - Drugs

Record: 35

07/09/2019

Company Report

Pages: 6

Senior Science Advisor Appointed; Near-Term Revenue Opportunity; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: CytoDyn Inc.

Industry: Medical - Drugs

Record: 36

06/18/2019

Company Report

Pages: 6

Leronlimab to Enter Clinical Study as Pre-Exposure Prophylaxis in HIV; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: CytoDyn Inc.

Industry: Medical - Drugs

Record: 37

05/08/2019

Company Report

Pages: 5

Fast Track Designation Granted for Leronlimab in Triple-Negative Breast Cancer; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: CytoDyn Inc.

Industry: Medical - Drugs

Record: 38

04/12/2019

Company Report

Pages: 6

Positive Recommendation for Ibalizumab in Europe Bodes Well for Leronlimab; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: CytoDyn Inc.

Industry: Medical - Drugs

Record: 39

04/03/2019

Company Report

Pages: 6

Manufacturing Agreement with Samsung BioLogics Inked; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: CytoDyn Inc.

Industry: Medical - Drugs

Record: 40

03/27/2019

Company Report

Pages: 5

Leronlimab Delivers 90% Response Rate as Monotherapy for HIV; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party